Allogene's new CEO Zachary Roberts outlined a strategic refocus on leveraging the intrinsic advantages of allogeneic (off-the-shelf) CAR-T — ready availability, consistent product quality, and ability ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
The chatter on ALLO is a mix of cautious optimism and technical skepticism. Here’s what’s trending: Traders are watching key support and resistance levels after a volatile breakout, wary of a bull ...
Allora's price outlook hinges on adoption versus token unlocks in a volatile AI-crypto niche. Adoption vs. Unlocks – Only ~20% of the 1B ALLO supply circulates, with major backer unlocks extending to ...
Ready to watch 'Allo 'Allo!? This 1984 Comedy/War & Politics series is available to watch right now. It's currently streaming on Amazon Prime Video, Peacock Premium, BritBox, Peacock Premium Plus, ...
The United States wants a reactor on the moon by 2030. A Russian-Chinese alliance is working on one for 2036. Some leading scientists say the danger is great. By Selam Gebrekidan Selam Gebrekidan ...
Allogene Therapeutics presented positive Phase 1 data from its TRAVERSE study of ALLO-316, an allogeneic CAR T therapy, for renal cell carcinoma (RCC) at the 2025 ASCO Annual Meeting. The study showed ...
Prof G Markets is your daily briefing on the news moving markets — from earnings and geopolitics, to Big Tech and AI. Hosted by Scott Galloway and Ed Elson, we cut through the noise with no-BS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results